Source facts
FDA issued an approval letter for ICOTYDE on 2026-03-19. The source metadata identifies NDA 220149 as an original application. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
ICOTYDE — FDA Approval Letter (NDA 220149)
Issued to JANSSEN BIOTECH. Application is approved as submitted.
Issued
March 19, 2026Application
NDA 505b1 • 220149
Product
ICOTYDE
Company
JANSSEN BIOTECH
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for ICOTYDE?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: NDA 220149.
- 3Submission: original application.
- 4Sponsor: JANSSEN BIOTECH.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the ICOTYDE approval letter
Is ICOTYDE FDA approved?
This letter documents an FDA approval action: FDA approved NDA 220149 for ICOTYDE, sponsored by JANSSEN BIOTECH, on March 19, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is NDA 220149?
NDA 220149 is the application under which FDA issued this approval letter for ICOTYDE to JANSSEN BIOTECH. The letter is dated March 19, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.